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Abstract 26 
Antibiotic susceptibility testing (AST) in Neisseria meningitidis is an important part of the 27 
management of invasive meningococcal disease. It defines minimal inhibitory concentrations 28 
(MICs) of antibiotics that are used in treatment and/or prophylaxis and that mainly belong to 29 
beta-lactams. The interpretation of the AST requires breakpoints to classify the isolates into 30 
susceptible, intermediate or resistant. The resistance to penicillin G is defined by MIC>0.25 31 
mg/L and that of amoxicillin is defined by MIC>1 mg/L. We provide data that may support 32 
revision of resistance breakpoints for beta-lactams in meningococci.   33 
We used experimental intraperitoneal infection in 8-week-old transgenic female mice 34 
expressing human transferrin and human factor H. Dynamic bioluminescence imaging was 35 
performed to follow the infection by bioluminescent meningococci with different MIC. Three 36 
hours later, infected mice were treated intramuscularly using several doses of amoxicillin or 37 
penicillin G. Signal decreased during infection with meningococci with the strain showing 38 
MIC of 0.064 mg/L of penicillin G with all doses. Signals only decreased for the strain with 39 
MIC of 0.5 mg/L of penicillin G after treatment with the highest doses corresponding to 40 
250,000 units/kg of penicillin G or 200 mg/kg of amoxicillin although to a slower rate than 41 
the strain with MIC of 0.064 mg/L. The decrease of bioluminescent signals was associated 42 
with a decrease in the levels of the pro-inflammatory cytokine, IL-6.  Our data suggest that 43 
high dose of amoxicillin or penicillin G can reduce growth during infection by isolates 44 
showing MIC of penicillin G of > 0.25 mg/L and ≤ 1mg/L. 45 
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Introduction 51 
Neisseria meningitidis is a Gram negative bacterium frequently encountered in human 52 
nasopharynx but it is also the causative agent of invasive meningococcal disease (IMD) that 53 
provokes mainly septicemia and meningitis. Neisseria meningitidis remains susceptible to 54 
beta-lactams, the antibiotics of choice in the treatment of IMD (1). Resistance to beta-lactams 55 
in meningococci is extremely rare, but reduced susceptibility has been described to penicillin 56 
G and to amoxicillin (intermediate isolates, PenI). However, neither resistance nor reduced 57 
susceptibility to cephalosporin of third generation has been detected so far (2). The 58 
proportions of PenI isolates differ worldwide and are increasing in several countries and can 59 
reach >30% of total meningococcal isolates (3-7).  60 
We have previously shown direct correlation between the polymorphism of penA gene 61 
encoding the penicillin binding protein 2 (PBP2) and the PenI phenotype. This phenotype 62 
seems to result from the reduced affinity of penicillin G and amoxicillin to PBP2 as well as to 63 
modification of peptidoglycan structure in PenI isolates with increased pentapeptide-64 
containing muropeptides (8).  Horizontal interspecies DNA exchanges in the genus Neisseria 65 
are suggested to drive the polymorphism of penA (7). Antibiotic susceptibility testing (AST) 66 
is mandatory for beta-lactam antibiotics and requires reliable breakpoints to inform decision 67 
making in patient treatment. 68 
In order to consistently define breakpoints, sequencing of penA from a large collection of 69 
isolates allowed  linking wild-type alleles of penA to low minimal inhibitory concentration 70 
(MIC) for penicillin G (<0.125 mg/L)(7). This defined the epidemiological cut off values for 71 
susceptibility to penicillin G of MIC to be lower than 0.125 mg/L and <0.250 mg/L for 72 
amoxicillin (7). It divided the meningococcal population into one part containing isolates 73 
harboring wild-type alleles of penA and another part comprising isolates showing highly 74 
diverse penA alleles and MICs of  ≥0.125 mg/L and 0.250 mg/L for penicillin G and 75 
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amoxicillin, respectively (7). The value of MIC<0.125 mg/L was preferred to define the 76 
susceptibility to penicillin G as it allows to fill the important rule to not split wild-type MIC 77 
distribution (9) as isolates with wild type penA showed MIC of 0.094 mg/L(7). These values 78 
fitted with those used by the European Committee for Antimicrobial Susceptibility Testing 79 
(EUCAST; http://www.eucast.org) and the Clinical and Laboratory Standards Institute 80 
(CLSI)(10).  81 
Intermediate isolates are expected to be treatable by beta-lactams, i.e. bacteria growth is 82 
reduced and/or bacteria are cleared from biological fluids. However, the higher limit of PenI 83 
isolates is still to be determined. EUCAST and CLSI indicate that isolates with MIC of 84 
penicillin G and amoxicillin >0.250 mg/L and >1mg/L respectively are resistant (PenR) to 85 
these beta-lactams (i.e. non treatable/treatment failure). However, isolates with MIC of 86 
penicillin G >0.250 mg/L harbor similar modified penA alleles as PenI isolates (7). The 87 
definition of resistant breakpoints is mainly driven by pharmacokinetic (PK) and 88 
pharmacodynamic (PD) indices that reflect antibiotic concentration and its effect respectively. 89 
However, experimental data are needed to correlate breakpoints to treatment. The use of 90 
animal models may help testing whether these breakpoints correspond to resistance and 91 
treatment failure. 92 
 93 
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Materials and Methods 101 
Ethics Statement 102 
This study was carried out in strict accordance with the European Union Directive 103 
2010/63/EU (and its revision 86/609/EEC) on the protection of animals used for scientific 104 
purposes. Our laboratory has the administrative authorization for animal experimentation 105 
(Permit Number 75-1554) and the protocol was approved by the Institut Pasteur Review 106 
Board that is part of the Regional Committee of Ethics of Animal Experiments of Paris region 107 
(Permit Number: 99-174). 108 
Meningococcal isolates: Phenotypic and Genotypic characterization 109 
Two clinical isolates of N. meningitidis were used (LNP24198 and LNP27704). Both isolates 110 
were of serogroup C and belonged to the clonal complex ST-11 (cc11). They harbored 111 
respectively the penA alleles penA3 and penA9 corresponding to a wild-type and a modified 112 
alleles respectively. MIC of penicillin G was determined as previously recommended using 113 
Etest with Mueller-Hinton agar supplemented with sheep blood (11) and were 0.064 mg/L 114 
and 0.5 mg/L respectively. MICs of amoxicillin were 0.125 and 1.5 mg/L respectively.  115 
Bioluminescent variants of both isolates were constructed by transformation with the 116 
recombinant plasmid pDG34, which carries the bioluminescent luxCDABE operon under the 117 
control of the porB promoter (12) and named LNP24198lux and 27704lux. Both strains were 118 
checked for their MICs of penicillin G, and for amoxicillin and their penA alleles verified by 119 
sequencing, showing that they were identical to the parent isolates. Both strains grew 120 
similarly on meningococcal growth medium.  121 
Mice infection and dynamic live imaging studies  122 
We took advantage from the availability of an animal model to study N. meningitidis 123 
infection, the transgenic mice expressing the human transferrin, since an iron source is 124 
required for meningococcal growth (13). We have recently developed another animal model, 125 
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a transgenic mice expressing the human factor H (fH) that allowed binding of this negative 126 
regulator of complement pathway on bacterial surface and hence allowing meningococci to 127 
escape complement-mediated lysis (14). The two types of mice were crossed to generate 128 
transgenic mice expressing both human transferrin and human fH that we used in infection 129 
experiments using bioluminescent meningococcal strains with different MIC to penicillin G 130 
and amoxicillin. Mice were in-house bred and were kept in a biosafety containment facility, in 131 
filter-topped cages with sterile litter, water and food, according to institutional guidelines.  132 
    Mice were infected by intraperitoneal route (i.p.) with standardized inoculate of 5×106 133 
bioluminescent colony forming units (CFU) per mouse in 0.5 ml of bacterial suspension. At 134 
the time point of 3 h the mice were divided into three groups that were treated by either 135 
penicillin G or amoxicillin only once by intramuscular injection in the interior face of the left 136 
thigh. The following increasing unique doses (per mouse) of penicillin G (60,000 units/kg, 137 
120,000 units/kg or 250,000 units/kg; corresponding to 37mg/kg, 75 mg/kg and 150 mg/ml) 138 
or of amoxicillin (50 mg/kg, 100 mg/kg and 200 mg/kg). The highest doses of both antibiotics 139 
corresponded to a daily dose used in treatment of IMD in humans. A group of two mice were 140 
only injected with saline as control. Interleukin-6 (IL-6) levels were also assayed in blood at 141 
the end point (8 h) as previously described (15). As similar results were obtained from both 142 
experiments with penicillin G and amoxicillin, IL-6 was tested for mice experiment treated 143 
with amoxicillin.   144 
Bacterial infection images were acquired after 0.5 h, 3 h, 6 h and 8 h of infection using an 145 
IVIS 100 system (Xenogen Corp., Alameda, CA) as previously described (13). Analysis and 146 
acquisition were performed using Living Image 4.3.1 software (Xenogen Corp.). Data were 147 
analyzed by linear regression using GraphPad InStat version 3.06 (GraphPad Software, San 148 
Diego, CA, USA).  149 
 150 
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Results 151 
 152 
Impact of MIC on amoxicillin treatment during meningococcal infection in mice 153 
In order to test the evolution of the experimental infection in vivo, transgenic mice were 154 
infected i.p. by the LNP24198lux (MIC penicillin 0.064 mg/L and amoxicillin 0.125 mg/L) or 155 
the strain LNP27704 (MIC penicillin 0.5mg/L and amoxicillin 1.5 mg/L). After 3 h of 156 
infection, infected mice were divided into groups that were treated by one of the three 157 
antibiotic doses (Amoxicillin or penicillin G). A group of mice was left untreated as a control 158 
group. 159 
After bacterial intraperitoneal challenge, dynamic bioluminescence imaging showed that 160 
30 min after the bacterial suspension injection, bacteria were mainly present in the peritoneal 161 
cavity in both types of strains LNP24198lux (MIC penicillin 0.064 mg/L and amoxicillin 162 
0.125 mg/L) and LNP27704lux (MIC penicillin 0.5 mg/L and amoxicillin 1.5 mg/L). Signal 163 
increased in all mice after 3 h of infection. For mice infected with the strain LNP24198lux 164 
and 6 h after infection (3 h after treatment with amoxicillin), the signal decreased in mice 165 
treated with 200 mg/kg dose and were cleared after 8 h of infection (5 h after treatment). For 166 
the two other doses, the signal only decreased after 8 h of infection (5 h after treatment). In 167 
the untreated mice, signal continued to increase in all time points (Fig.1A). For mice infected 168 
with the strain LNP27704lux (MIC penicillin 0.5 mg/L and amoxicillin 1.5 mg/L), the 169 
bioluminescent signal decreased only in mice treated with the highest dose (200 mg/kg) while 170 
signal continued to increase in mice treated with 50 mg/kg and 100 mg/kg and did not differ 171 
from the signal observed in untreated mice (Fig.1B). 172 
Linear regression analysis confirmed the significant decrease of bacterial viability for the 173 
strain LNP24198lux in amoxicillin-treated mice in a dose-dependent manner. Negative slopes 174 
were also significantly different from the slope of untreated mice (P<0.01 and r2 of 0.38 and 175 
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0.85 respectively for 100 mg/kg and 200 mg/kg doses) (Fig. 1A; 1B). However, for the dose 176 
of 50 mg/kg, the slope was not significantly different from zero (P=0.77 and r2=0.007) 177 
suggesting bacteriostasic effect (Fig.1A; 1B).  178 
For the strain LNP27704lux, only the 200 mg/kg dose resulted in a negative slope that 179 
differed significantly from that observed with untreated mice and from the other doses of 180 
amoxicillin-treated mice (P<0.001 and r2=0.59). For the strain LNP27704lux treated with the 181 
two other doses (50 mg/kg and 100 mg/kg) the slopes were positive and similar to those of 182 
untreated mice suggesting bacterial growth (Fig. 1A; 1B). For the 200 mg/kg-treated mice, 183 
the r2 values for the strain LNP27704lux was lower than that for strain LNP24198lux (0.59 184 
versus 0.85 respectively) suggesting slower clearance of the former strain. 185 
We also performed similar experiments using penicillin G with (doses of 60,000 units/kg; 186 
125,000 units/kg and 250,000 units/kg). Mice were infected i.p. by the strain LNP27704 187 
(MIC penicillin 0.5mg/L and amoxicillin 1.5 mg/L) and after 3 h of infection, three groups of 188 
infected mice were treated by one of the three penicillin G doses. A group of mice was left 189 
untreated as a control. 190 
Bioluminescent signal increased and spread after 3 h of infection. After treatment, only the 191 
mice group treated with the highest dose (250,000 units/kg) showed a decrease of 192 
bioluminescent signal indicating loss of bacterial growth. The signal continued to increase in 193 
mice that were infected by LNP27704lux and treated with either 60,000 units/kg or 125,000 194 
units/kg of penicillin G (Fig. 1C). 195 
Linear regression analysis confirmed the impact of the highest dose in mice infected with 196 
the strain LNP27704lux. The highest dose resulted in a negative slope that differed 197 
significantly from that obtained with the other doses and untreated mice (P<0.001) with an r2 198 
value of 0.12. 199 
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For the mice infected by the strain LNP24198lux (MIC 0.064mg/L) and treated with 200 
penicillin G, the data were similar to those obtained with amoxicillin treatment (data not 201 
shown). 202 
All these data taken together suggest the highest dose, similar to the daily dose used in 203 
humans, leads to decrease of bacterial counts in mice even if the strain is considered PenR. 204 
 205 
Decreased inflammatory response in mice treated with optimal amoxicillin dose 206 
We next assayed the levels of IL-6, a proinflammatory cytokine at 8 h post-infection. The 207 
data are showed in Table 1 and clearly suggest a dose dependent decrease of IL-6 levels in 208 
amoxicillin-treated mice that were infected by the strain LNP24198lux (MIC penicillin 0.064 209 
mg/L and amoxicillin 0.125 mg/L). These levels were not detectable in mice treated with 200 210 
mg/kg of amoxicillin. On the other hand, mice infected with the strain LNP27704lux (MIC 211 
penicillin 0.5 mg/L and amoxicillin 1.5 mg/L), and treated with 50 mg/kg and 100 mg/kg of 212 
amoxicillin showed similar levels of IL-6 as obtained in untreated mice (Table). IL-6 level 213 
was not detectable in mice treated with the highest dose (200 mg/kg of amoxicillin). 214 
 215 
 216 
 217 
 218 
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 220 
 221 
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Discussion 225 
We have previously emphasized the advantages of in vivo bioluminescent imaging for real-226 
time monitoring of meningococcal infections and their treatment (13, 16). This technology is 227 
sensitive, rapid and non-invasive. It limits animal-to-animal variation and reduces the number 228 
of animal used. In the present study, we adapted this system to evaluate the correlation of 229 
beta-lactams breakpoints during experimental meningococcal infection in transgenic mice. 230 
N. meningitidis is intrinsically susceptible to many antibiotic classes and MIC50 and MIC90 231 
values (antibiotic concentrations respectively inhibiting 50% and 90% of a sample of strains) 232 
are very low(17). Meningococcal resistance to beta-lactams remains rare and meningococcal 233 
strains remained susceptible to penicillin G with an MIC50 of penicillin G of 0.06 mg/L. Few 234 
old reports described rare beta-lactamase producing strains with MICs that may reach or 235 
exceed 256 µg/ml (18, 19). These beta-lactamases are plasmid-borne TEM-1 type enzymes 236 
similar to those described in Neisseria gonorrhoeae that inactivate penicillin G and 237 
amoxicillin but does not hydrolyze third generation cephalosporins (18). However, isolates 238 
with reduced susceptibility to penicillin G and amoxicillin are quite frequent worldwide (7). 239 
The MICs of amoxicillin and penicillin G for these intermediate isolates remain low and 240 
defining the upper limit of the critical values remains problematic.  241 
Although treatment failures have been described for strains with the highest MICs (20), the 242 
severe infections caused by these strains generally resolve favorably using high doses of 243 
penicillin G or amoxicillin, which allow bactericidal concentration to be reached in 244 
cerebrospinal fluid. The effect of beta-lactams is dependant on the time the antibiotic 245 
concentration exceeds  its MIC for the microorganism (T > MIC) (9). Our data with the 246 
highest dose of antibiotics are in agreement with this consideration. This dose corresponds to 247 
the recommended total daily dose for the treatment of IMD (21). Our data suggest that the 248 
strain with MIC of 0.5 mg/L may not be classified as resistant to penicillin G as it was 249 
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treatable. However, lower doses of penicillin G and amoxicillin failed to control the bacterial 250 
growth and may lead to treatment failure. As the threshold of 1 mg/L corresponds to the 251 
effective therapeutic concentration in the CSF obtained during treatment with penicillin G 252 
(22), we may suggest that the upper breakpoint for penicillin G to by 1 mg/L and thus 253 
intermediate isolates may be defined as those with MIC ≥0.125mg/L and ≤1mg/L. This range 254 
also contains the isolates with altered penA alleles that all shared the same altered residues (7). 255 
Isolates with MICs >0.25 mg/ml and ≤ 1mg/ml may not be considered as PenR isolates. 256 
Indeed, the drug effect, in vivo, is subjective to bacterial growth rate but is also dependant on 257 
host defense mechanisms. These latter aspects are not directly considered by the conventional 258 
PK/PD model but can be addressed using relevant animal models as described in this work.  259 
IL-6 is considered to be an important mediator of acute inflammatory responses to bacterial 260 
infection (23). After 8 h of infection, the levels of IL-6 increased in mice infected by both 261 
isolates and were higher in mice infected by the susceptible strain (LNP24198lux) than in 262 
mice infected by the resistant isolate (LNP27704lux). This is in agreement with our previous 263 
study that meningococcal isolates with modified PBP2 showed significant lower induction of 264 
the inflammatory response (15).  The mice treated with the higher dose did not show any 265 
detectable IL-6. The trends of IL-6 levels in amoxicillin treated groups followed the 266 
microbiological results. Our data are consistent with previous reports suggesting that IL-6 was 267 
a possible indicator of bacterial killing (24). 268 
Finally, our data suggest that if amoxicillin and penicillin G are to be used in treatment of 269 
IMD prior determination of MIC, the first dose should be 200 mg/Kg and 250,000 units/kg 270 
respectively. 271 
Our findings clearly highlight a powerful approach in defining breakpoints through the 272 
analysis the polymorphism of the gene encoding the targets of the antibiotics to characterize 273 
the alterations of the targets and their correlation with MIC. The use of animal models in 274 
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association with PK/PD analysis can then allow defining the breakpoints. Finally, the increase 275 
of MIC in meningococci may also correspond to other undefined mechanisms that require 276 
additional studies. However, our proposal for a breakpoint for resistance to penicillin G 277 
higher than 1 mg/L fits with other breakpoints for pathogens showing meningeal tropism (25). 278 
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Legend to Figure 402 
 Figure 1. Transgenic mice were infected i.p. with standardized inocula of 5×106 403 
bioluminescent colony forming units (CFU) per mouse in 0.5 ml of bacterial suspension. 404 
Quantification was performed after 30 min, 3 h, 6 h and 8 h of infection by defining regions 405 
of interest (the whole mouse). After 3 h of infection, mice were treated with the unique 406 
indicated doses of amoxicillin or penicillin G by intramuscular injection in the interior face of 407 
the left thigh. The untreated mice received an injection with the same volume of physiological 408 
serum. Left side is the bioluminescent image and the right side is the linear regression 409 
analysis of the evolution of bioluminescent signals after treatment. Linear regression data are 410 
shown as solid lines with colors corresponding to the indicated tested condition with dashed 411 
color-matched lines corresponding to the 95% confidence band  (A). Amoxicillin treatment 412 
data for the strain LNP24198lux (MIC of 0.064 mg/L  and  0.125 mg/L  of penicillin G and 413 
amoxicillin respectively). (B) and (C) Amoxicillin treatment and penicillin G treatment 414 
respectively for the strain LNP27704lux (MIC of 0.5 mg/L and 1.5 mg/L of penicillin G and 415 
amoxicillin respectively). The doses of amoxicilline (in mg/kg A and B) and those of 416 
penicillin G (in units/kg in C) are shown to the left. 417 
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Table 1. Il-6 levels in mice presented in figure 1 after 8 hours of infection. 
Strain tested Antibiotic dose 
IL-6 Mean 
(µg/ml) 
95% CI of the 
mean P value 
LNP24198lux  
(0.125 mg/L)     
 untreated 10.4 3.8 - 16.9 Ref 
 50 mg/kg 14.4 -8.1 -  36.9 Ref 
 100 mg/kg 1.8 -0.7 - 4.2 Ref 
 200 mg/kg ND   
LNP27704lux (1.5 
mg/L)     
 untreated 2.8 0.6 - 5 0.01 
 50 mg/kg 4.2 0.6-7.7 0.25 
 100 mg/kg 4.3 0.1 -  8.5 0.2 
 200 mg/kg ND   
ND: Non Detectable 
CI: Confident interval  
Ref: The PenS isolate (LNP24198lux) was used as a reference for the comparison with the 
PenR isolate (LNP27704). 
 
 
